Skip to main content
AmigoFish

The Uromigos

The UromigosAudio

Format:
Podcast
New episodes:
Daily
Typical length:
about 40 minutes
Latest episode:
Not rated yet

About this show

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Covers: oncology, genitourinary cancer, renal cell carcinoma, prostate cancer, bladder cancer, antibody drug conjugates, cancer immunotherapy, circulating tumor dna

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

The Uromigos is a podcast on the latest developments in genitourinary cancer, hosted by Brian Rini and Tom Powles. Recent episodes cover T cell engagers in kidney cancer, doublet therapy in renal cell carcinoma, prostate cancer sequencing, and antibody drug conjugates and ctDNA in bladder cancer.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • Episode 520: ESMO 2026 Preview

    · 54 min

    Silke, Brian and Tom preview the major data to be presented at ESMO 2026

    Not rated yet
  • Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?

    · 33 min

    Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).

    Not rated yet
  • Episode 518: PSMAddition in Clinical Practice

    · 31 min

    Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk

    Not rated yet
  • Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

    · 40 min

    Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.

    Not rated yet
  • Episode 516: The Influence of Hypoxia on Response and Resistance in RCC

    · 47 min

    Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.

    Not rated yet
  • Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala

    · 43 min

    Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

    Not rated yet
  • Episode 514: Artificial Intelligence in Cancer Drug Development

    · 40 min

    Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

    Not rated yet
  • Episode 513: Trials and Tribulations of Investigator-initiated Research

    · 25 min

    Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.

    Not rated yet
  • Episode 512: ENZA-P Nature Medicine translational data

    · 31 min

    In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.

    Not rated yet
  • Episode 510: ADCs in Prostate Cancer

    · 30 min

    Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

    Not rated yet
  • Episode 509: ASCO 2026 Review

    · 55 min

    This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology.

    Not rated yet
  • Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer

    · 39 min

    Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

    Not rated yet
  • Episode 507: ASCO 2026 - TALAPRO-3

    · 41 min

    Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.

    Not rated yet
  • Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?

    · 19 min

    This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and innovative approaches to assessment. Experts discuss the limitations of current tools, the importance of long-term follow-up, and future directions for integrating patient-centered metrics.

    Not rated yet
  • Episode 505 : ASCO 2026 - RAMPART

    · 29 min

    James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

    Not rated yet
  • Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

    · 40 min

    This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

    Not rated yet
  • Episode 499: APCCC 2026 - Radioligands in Prostate Cancer

    · 37 min

    This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.

    Not rated yet
  • Episode 503: ASCO 2026 Preview

    · 1 hr 22 min

    Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026

    Not rated yet
  • Episode 502: AUA 2026 and FDA bladder cancer meeting

    · 35 min

    In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies

    Not rated yet
  • Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer

    · 19 min

    Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.

    Not rated yet